Website: https://www.fountbio.com/platform/

Booth number: F143

Company profile

Medical aesthetic treatments that deliver crosslinked HA into the dermis (i.e., injectable HA skinboosters) are clinically demonstrated to provide long-lasting improvements in skin texture appearance and smoothness. The challenge of current HA treatments is that they require up to 100+intradermal injections for a full-face. Fount Bio is developing an innovative new aesthetic HA treatment, Fli-Derm™, based on the Nobel Prize winning field of bio-orthogonal “click” chemistry. In contrast to current treatments, Fli-Derm delivers non-crosslinked HA directly into the superficial dermis without injection. Once inside the dermis, Fli-Derm’s active components undergo spontaneous and rapid crosslinking to establish a durable, well-integrated bio-polymer layer. Fli-Derm treatment is fast, and anesthesia is not required. Initial clinical studies have shown Fli-Derm to be safe and effective for reducing fine lines and wrinkles. PhII (feasibility) studies are scheduled to start in early 2026